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Abstract: Despite the availability of multimodal and aggressive therapies, currently patients with
skeletal sarcomas, including osteosarcoma and chondrosarcoma, often have a poor prognosis.
In recent decades, advances in sequencing technology have revealed the presence of RNAs without
coding potential known as non-coding RNAs (ncRNAs), which provides evidence that protein-coding
genes account for only a small percentage of the entire genome. This has suggested the influence
of ncRNAs during development, apoptosis and cell proliferation. The discovery of microRNAs
(miRNAs) in 1993 underscored the importance of these molecules in pathological diseases such as
cancer. Increasing interest in this field has allowed researchers to study the role of miRNAs in cancer
progression. Regarding skeletal sarcomas, the research surrounding which miRNAs are involved
in the tumourigenesis of osteosarcoma and chondrosarcoma has rapidly gained traction, including
the identification of which miRNAs act as tumour suppressors and which act as oncogenes. In this
review, we will summarize what is new regarding the roles of miRNAs in chondrosarcoma as well as
the latest discoveries of identified miRNAs in osteosarcoma.
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1. Introduction
In the last century, one of the most important scientific discoveries has been the identification
of RNAs without coding potential. Scientists have reported the presence of these RNAs, which are
known as non-coding RNAs (ncRNAs), based on their peculiarity. This heterogeneous group of
molecules is classified based on their size as: (1) long non-coding RNAs (lncRNAs), which are longer
than 200 base pairs; (2) small non-coding RNAs, which have a maximum length of 200 base pairs;
or (3) circular RNAs (circRNAs), which are small covalently closed circular loop structures with either
5′ to 3′ polarity or polyadenylation at the 3′ ends [1]. Among these subclasses, microRNAs (miRNAs or
miRs) are the most extensively well-known and well-studied ncRNAs. Because these molecules appear
to play an important role in cellular biology, more investigations are necessary to elucidate their
true functions.
If we look at the history of this research field, which can be defined as the “world of ncRNAs”,
it started in the mid- to late-twentieth century. In 1993, Lee et al. [2] discovered for the first time the
presence of small RNAs during their research on Caenorhabditis elegans; these molecules were able to
control biological processes, including the regulation of gene expression [3–5].
In their studies, Lee and colleagues observed the presence of an ncRNA and, believing that this
molecule could exert temporary effects, they defined this as a small temporal RNA (stRNA) called lin-4.
Lin-4 has been observed to regulate the transcription of proteins such as lin-14 and thus
standardize the timing of larval development in C. elegans.
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After some years, Reinhart et al. [6] discovered, while also working on C. elegans, another stRNA
called lethal-7 (let-7). This molecule was reported to be involved in the translational repression of the
gene lin-41, which participates in the larval development of C. elegans.
After the discovery of more stRNAs in C. elegans, other reports began describing these same
molecules in mammals [7] and humans [8]. This discovery was critical because it served as proof
that these small RNAs are well conserved and acted as important gene regulators [9,10]. For this
reason, this class of molecules was redefined as small non-coding RNAs (sncRNAs), which are not
temporary molecules. From these first studies, scientific interest around these small molecules has
increased, and the subclass of microRNAs (miRNAs or miRs) has become the most investigated and is
currently the most well-known of the ncRNAs [11]. At the same time, the other two classes of ncRNAs
(lncRNAs and circRNAs) have begun to garner increasing interest.
The recent discovery of circRNAs has changed the idea about RNAs as a solely linear entity.
These small well-conserved circular molecules have several properties thanks to their unique features.
The first reported circRNA, Sry, acts as a sponge for miR-138 [12]. Additional studies on circRNAs are
needed to understand their potential role and elucidate their effect in contributing to the diversity and
complexity of eukaryotic transcriptomes.
lncRNAs include molecules that are longer than 200 base pairs; however, they are not always as
well conserved as miRNAs and circRNAs [13]. Despite this, some lncRNAs are well characterized
and highly conserved [i.e., X inactive specific transcript (Xist), hi antisense Tsix (TSIX transcript, XIST
antisense RNA) [14] and HOX antisense intergenic RNA (HOTAIR) [15]]. In contrast, a high number of
conserved lncRNA promoter sequences has been observed, which demonstrates that their regulation is
very important [16]. Despite their expression levels, which are lower than those of miRNAs, lncRNAs
can be found in many tissues, and they are often tissue-specific.
lncRNAs are present in the cytoplasm and the nucleus, where the majority remain after synthesis.
Their synthesis is mediated by the transcriptional machinery of RNA Polymerase II (Pol II) and by
RNA Polymerase III (Pol III). Pol II transcribes lncRNAs that are associated with chromatin and are
processed as classical mRNAs with transcriptional elongation and polyadenylation. However, Pol III
transcribes other nonpolyadenylated lncRNAs that fold into tertiary structures [16–19].
Based on several studies on the localization of lncRNAs inside the genome they have been divided
into intergenic, intronic, bidirectional, sense and antisense lncRNAs [20–24]. Because of their length,
lncRNAs can form complex structures, including helices and hairpin loops, by which they can interact
with DNA, RNA and proteins [13,25].
Recent studies have shown that lncRNAs can behave as signals or decoys by negatively regulating
transcription, as guides for ribonucleoprotein (RNP) binding, as an interactive molecule that binds
to target genes either in cis or in trans, and as scaffolding molecules. Regarding scaffolding activity,
lncRNAs act as a platform and can create RNP complexes known as lncRNA-RNPs, which can remodel
chromatin via histone methylation with the help of polycomb group proteins (PcG) [26].
Some studies have also revealed the ability of lncRNAs to not only act as transcriptional or
post-transcriptional regulators but also function in a manner analogous to classical miRNAs by coding
for micropeptides and engaging with ribosomes [27].
Another important function of lncRNAs is to regulate miRNA activity by acting as either a
competitive endogenous RNA (ceRNA) or as an miRNA sponge [28–30]. ceRNAs have been described
as lncRNAs that, having one or more sequences similar to RNAs, regulate transcription by sequestering
molecules that act as regulatory transcription factors, catalytic proteins and miRNAs [30]. However,
lncRNA sponges are complex structures that present binding sites for one or more miRNAs and
thereby act to regulate the effects of miRNAs [31].
The literature on lncRNAs and miRNAs has highlighted both classes of molecules as important
regulators of physiological cellular processes such as development, proliferation, apoptosis and
migration [3,11,32,33]. These ncRNAs are also involved in pathological processes associated with
human diseases, including cancer [34–36].
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Some physiological processes that lncRNAs control include pluripotency and lineage commitment,
as described for the lncRNA Tcl 1 upstream neuron-associated (TUNA) lincRNA, which are also known
as TUNA factors. lincRNA can bind Sox2, Nanog and Fgf4 (three pluripotency transcription factors),
thereby preventing the suppression of miRNAs and maintaining the self-renewing potential of human
embryonic stem cells [37]. Another important physiological lncRNA is Braveheart (Bvht), which was
discovered in a study on cardiovascular development and is fundamental in the development of
cardiovascular progenitor cells [38]. A recent study showed that lncRNAs are involved in human
pregnancy. In fact, the lncRNA Meg3 has been reported to be important in reducing the risk of
apoptosis and promoting the migration of trophoblasts [33]. Regarding their role in pathological
cellular processes, lncRNAs are involved in cardiovascular diseases [39], fibrotic diseases [40,41] and
cancer development. Scientists have observed that lncRNAs can either promote or suppress several
types of cancers, and an especially strong interaction between lncRNAs and miRNAs could be the
basis of tumour development [16,42,43].
Several recent studies on the role of lncRNAs in cancer have shed light on which ones
are onco-lncRNAs (enhancing tumour growth) and which ones are tumour suppressor lncRNAs
(inhibiting tumour progression). A study on hepatocellular carcinoma reported that the lncRNA
PTENP1 and its target tumour suppressor gene PTEN are important in mitigating tumour growth. It
has been documented that both genes are lost during the progression of several cancers. Restoring
the levels of lncPTENP1 leads to inhibition of tumour growth and enhanced autophagy. Further
investigations revealed that lncPTENP1 acts as a sponge for miR-17, miR-19b and miR-20a, all of which
target and block the expression of genes responsible for autophagy. Hence, the tumour suppressor
function of lncPTENP1 is blocking these miRNAs to remove their inhibition on autophagy [44].
In contrast, lncATB has been recognized as an onco-lncRNA that is overexpressed in all breast
cancer patients who exhibit resistance to trastuzumab chemotherapy. Studying the activity of lncATB,
scientists observed that this lncRNA binds miR-200c, a tumour suppressor that prevents the epithelial
to mesenchymal transition (EMT). Therefore, lncATB, by blocking miR-200c, promotes invasion and
metastasis of cancer cells [45]. There are also recent studies demonstrating that lncRNAs can be targets
for miRNAs. A report on prostate cancer suggested that the interaction between miR-34a and HOTAIR,
a well-conserved lncRNA, can mitigate the oncogenic effect of HOTAIR. Furthermore, miR-34a binding
to HOTAIR results in knockdown of HOTAIR, thus causing a decrease in prostate cancer cell growth
and metastasis [46].
Another important pathological process that involves ncRNAs is tumour angiogenesis, which
is fundamental for cancer development as a response to hypoxic conditions within the tumour
microenvironment and as a method to supply the nutrients necessary for continued growth of the
tumour bulk. Tumour angiogenesis is a complex process that results from the balance between
pro-angiogenic and anti-angiogenic factors within the tumour microenvironment. Recent studies have
shown how angiogenesis is modulated by ncRNAs; specifically, lncRNAs and miRNAs [47]. As in
cancer development, ncRNAs they can affect each other in several ways within the process of tumour
angiogenesis. One example is the interaction between miR-9 and lncMALAT1. lncMALAT1 has been
described as a pro-angiogenic factor in cancer stem cells (CSCs) by acting as a sponge for miR-200c
and miR-145, leading to subsequent upregulation of Sox2 and an eventual shift of the cell towards
more stem-like properties. The activity of lncMALAT1 is blocked by miR-9, and activation of AGO2 by
miR-9 results in the degradation of MALAT1. Thus, miR-9 inhibits the angiogenesis [48].
In summary, the last two decades have shown an increasing focus on the study of ncRNAs with
respect to the physiological and pathological processes. The discovery of the molecules involved in
the crosstalk among miRNAs, lncRNAs and circRNAs now represents an important challenge for
scientists in elucidating the complexity of these processes. Obviously, one of the most characterized
pathological processes is cancer. Although the study of lncRNAs and circRNAs in the context of cancer
development and progression is in its infancy (particularly for circRNAs), there is increasing literature
regarding the role of miRNAs in cancer progression.
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In fact, after identifying the importance of miRNAs in biological processes [4,49], researchers have
focused more on the role miRNAs in cancer progression. [50,51] Moreover, these small non-coding
RNAs, which play an important and complex role in post-transcriptional gene expression, can be
used as prognostic, diagnostic and predictive markers, but they can also be used as targets in the
development of new therapies [52,53].
Targeting miRNAs could be a valid solution for the challenges posed by researchers regarding
the possibility of developing novel and more effective anti-cancer therapies. In particular, for tumours
that are rare, have unknown aetiology and, despite the existence of aggressive therapies, have a poor
prognosis, there is often a lack of effective therapy.
One example of these difficult-to-treat tumours is sarcomas, specifically, bone sarcomas.
Despite available multimodal treatments, which include chemotherapy, surgery and radiotherapy,
the prognosis of these patients is still often poor. There are three types of primary bone sarcomas:
Ewing’s sarcoma, chondrosarcoma and osteosarcoma. These are very rare tumours characterized by a
poor 5-year survival rate from the time of diagnosis, despite recent advances treatment [54] Hence,
the scientific world has started to consider the role of miRNAs in these sarcomas in an attempt to
elucidate the tumour aetiology. The ultimate goal is to identify new molecular targets and develop
more effective anti-cancer therapies.
In this review, we provide a detailed description about the current progress of miRNA research
regarding osteosarcoma (OS) and chondrosarcoma (COS). We first provide an overview on the
role of miRNAs in physiological osteogenesis after a focused analysis on which roles are the bone
cancer-associated roles of miRNAs.
2. Biogenesis and Functions of miRNAs
After the discovery of these small RNA molecules in C. elegans (which have the ability to regulate
several biological processes) [2], the subsequent search for endogenous RNAs that can silence genes
has resulted in the discovery of a large family of small RNAs. The major class of this family is known
as microRNAs (miRNAs or miRs) [8,55,56].
Aside from miRNAs, two other classes of small RNAs have been identified—endogenous
small interfering RNAs (siRNAs) and Piwi-interacting RNAs—both of which are important in
genetic regulation [57,58]. miRNAs are endogenous single-strand RNAs 18-24 nucleotides in
length with the ability to regulate eukaryotic gene expression at the post-transcriptional level [59].
In 2003, over 200 miRNAs were experimentally discovered, and several have been identified using
computational approaches. Currently, over 2500 human miRNAs have been identified, and it is highly
likely that two-thirds of all human genes are directly targeted by these miRNAs [60,61]. However,
what is the origin of these endogenous small RNAs?
There are three different miRNA biosynthesis pathways. Two of these pathways are considered
alternative processing pathways; one regulates the biogenesis of only a small subset of miRNAs known
as mirtrons [62], and the other is related to the biogenesis of miR-451 [63]. The third pathway is the
canonical miRNA synthesis pathway.
Biogenesis starts in the nucleus where the miRNA genes are transcribed by RNA Polymerase II
to form primary hairpin transcripts (pri-miRNAs); afterwards, the pri-miRNAs are processed into
precursor miRNAs (pre-miRNAs) by an RNase endonuclease III called DROSHA, which is always
localized inside the nucleus.
The pre-miRNAs, which have a stem-loop secondary structure, must be exported to the cytoplasm
via the nuclear protein Exportin-5, a Ran-GTP-dependent transporter. Upon translocation into the
cytoplasm, the pre-miRNAs are processed by a second RNase III enzyme known as DICER.
At this point, the pre-miRNAs are now double-stranded miRNAs, which can form an active
RNA-induced silencing complex (RISC). This complex comprises a double-stranded miRNA associated
with the Argonaute 2 protein (AGO2), the key catalytic enzyme within the complex. Thus, RISC is the
necessary complex by which miRNAs post-transcriptionally silence gene expression.
Molecules 2017, 22, 417 5 of 29
In this complex, mature miRNAs usually bind their target mRNAs at the 3′ untranslated region
(3′ UTR) at a sequence of 6-8 base pairs called the “seed region” at the 5′ end of the mature miRNAs.
The short miRNA-mRNA binding site permits each miRNA to target more than one mRNA [62,64,65].
This described system is highly regulated and controls expression at the transcriptional level. This
allows for the tissue- and cell type-specific expression of miRNAs. The regulatory mechanisms act on
the two enzymes DROSHA and DICER, which are regulated by Di George syndrome critical region 8
(DGCR 8) and TAR RNA-binding protein (TRBP), respectively [66,67]. Several studies on miRNAs
have shown that one miRNA, based on its seed region, can target ~30% of expressed genes and is
highly tissue-specific and well conserved [68].
miRNAs are implicated in several physiological processes, such as development, proliferation,
differentiation and apoptosis in normal cells [4,69]. They are also involved in the maintenance of the
pluripotency. Different studies have showed the role of some miRNAs (i.e., miR-15a, miR-16, miR-19b,
miR-302 cluster, miR-290, let-7 miRNAs a, miR-34a and miR-145) in the physiology of embryonic
stem cells (ESCs) [18,70–73]. As several studies have suggested, miRNAs can either re-enforce the
pluripotent state or promote differentiation such that the final outcome in the cellular system is
synergistic and balanced.
Given these observations that the miRNAs mentioned above can act as promoters or suppressors
of pluripotency in ESCs, Zovoillis et al. [74] studied how overexpression of the miR-290 family enhances
cell proliferation by targeting p21, an inhibitor of cell proliferation, and maintains pluripotency because
it safeguards the expression of Lin28, an RNA-binding protein that prevents the maturation of the miR
let-7a, a strong promoter of cell differentiation and an inhibitor of miR-290 [75].
The realization that miRNAs are key molecules in normal cellular processes has paved the
way for the investigation of their roles in pathological conditions, especially cancer. Since their
discovery, the influence of miRNAs has been observed at several levels in the pathogenesis, progression,
development and invasion of cancer [53].
3. The Many Roles of miRNAs in Cancer: Oncogenes, Tumour Suppressors, Biomarkers and
Therapeutic Targets
In 2002, Calin et al. described for the first time that miRNA dysregulation could translate into
the manifestation of chronic lymphocytic leukaemia [50]. After their discovery, researchers began to
analyse how miRNAs contribute to diseases and disorders such as cardiovascular diseases [76],
fibrosis [77], diabetes [78], neurodegenerative diseases [79] and cancer [80]. In relation to their
expression and function inside the tumour bulk, miRNAs can behave either as an oncogene (onco-miR)
or as a tumour suppressor, and their function also changes in relation to the role of their mRNA
targets [80]. Based on the study regarding the functions of miRNAs in disease, scientists have realized
that these small molecules can be not only targets for the development of new therapies but also
be biomarkers for the same diseases. Obtaining a correct diagnosis early in the disease progression
is an important aspect for successfully treating diseases, especially tumours. A correct and prompt
diagnosis is fundamental fora good prognosis and a good response to anti-cancer treatments [53].
To date, the diagnostic standard of cancer diagnosis is often the histopathological analysis of a tumour
sample, which is usually obtained from a surgical biopsy. This method is not only invasive and
expensive but can also be dangerous for patients. So, finding new methods could be useful to improve
the diagnosis. One solution is identifying molecules that are specifically related to diseases and can
be detected within samples of biological fluids from humans. Consequently, since the discovery of
extracellular and circulating miRNAs, a probably approach appears to involved miRNAs. In 1947,
Mandel and Metais [81] observed the presence of circulating RNA and DNA in the plasma of healthy
and sick individuals. In the 1960s, circulating free nucleic acids (cfDNA/RNA) were detected in
patients with autoimmune diseases [82]. In 1977, Leon et al. [83] postulated for the first time the
potential of cDNAs as biomarkers. In 2007, scientists discovered the presence of miRNAs in the blood
of a lymphoma patient [84].
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Corsten et al. observed an increase in the levels of miR-208b and miR-499 in blood from patients
who recently experienced a myocardial infarction [85]. They hypothesized that this phenomenon
was related to a passive release of miRNAs into bodily fluids after tissue injury, cellular apoptosis or
necrosis. After these first studies on the presence of miRNAs in the body fluids (i.e., blood, saliva, and
urine) of both healthy and diseased people, the field of circulating miRNAs has expanded. Several
studies have shown that these molecules are highly stable in bodily fluids and are packaged into
exosomes [86,87], which are small (40–100 nm) membraned vesicles of endocytic origins that are
released by cells into the extracellular environment. These microvesicles might be a communication
method among cells. Exosomes have been studied in several cellular processes such as antigen
presentation on T-cells and metastasis [88].
Several cells are capable of releasing exosomes, and the composition (lipids, proteins) of the
vesicular membranes is an indicator of the origin and function of exosomes. Valadi et al. first
revealed the presence of small ncRNAs inside exosomes from cells [89], and Hunter and his
collaborators subsequently reported the presence of miRNAs in circulating plasma exosomes from
healthy patients [90]. In relation to this, scientists have started to think that individuals can be
identified using miRNAs circulating exosomes as a fingerprint; this method could distinguish healthy
and pathological conditions and serve as a novel diagnostic, prognostic and disease surveillance tool.
Unfortunately, we have yet to specifically and clearly identify all the miRNAs that are associated with
pathological disorders and cancer subtypes. Several research groups are working hard to identify
which miRNAs are specific for each different cancer type, which ones are always present in the
bodily fluids of patients, and which ones are possibly modulated in response to anti-cancer therapies.
Additionally, the origin of these exosomes containing miRNAs is also unclear. They can be released
by necrotic tumour cells, lysed tumour cells, cells from another tissue affected by an ongoing disease,
or the tumour itself, which actively secretes miRNAs into the surrounding environment. Therefore,
further studies in this field are necessary. However, although we do not have the entire map of all
the miRNAs that are specifically involved in a disease, we have identified some miRNAs that may be
specific to a disease and its stage; thus, these can be used as biomarkers [91].
In recent years, many studies have been published on how to detect miRNAs within bodily fluids
with the goal of applying the detection of miRNAs as a clinical diagnostic tool [92]. Several detection
methods for miRNA analysis have been implemented in a clinical setting [93]. The gold standard is
represented by amplification-based methods [94–96], followed by hybridization-based methods [97,98]
and microarrays [99], which are another powerful method that can also detect unknown miRNAs.
More recent techniques are based on capillary electrophoresis-mass spectrometry [100]; the creation
of new and simpler microarray platform that does not require RNA extraction, labelling and
target amplification [101] and a technique based on the use of a label-free miRNA electrochemical
biosensor [102]. In relation to this, before translating advanced technologies like miRNA serum
profiling into clinical practice, certain problems should be addressed. One is that the miRNA analysis
methods should be standardized; to achieve this, it is necessary to use the same extraction methods,
standardized platforms, target miRNAs and body fluids. However, we are still far from this goal, and
more research must be performed to develop a completely standardized protocol for the detection of
miRNAs in clinical practice.
Another important aspect critical for the future application of miRNA detection in clinical practice
is determining which miRNAs are specific for each cancer type and understanding the role of these
miRNAs in cancer progression (i.e., whether they are tumour suppressors or promoters) [92,93,103,104].
Recent studies have shown that miRNAs can act as tumour suppressors by targeting specific genes
or lncRNAs, which are known to be oncogenes, and subsequently blocking their cancerous potential
by inhibiting cancer invasion and proliferation. For example, miR-1, which has been described as an
important factor in the development of skeletal and myocardial muscle, acts as a tumour suppressor
in several cancers (i.e., lung cancer, hepatocellular carcinoma, colon cancer, OS, etc.); in fact, miR-1 is
downregulated in all these malignancies.
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This is related to the ability of miR-1 to target several genes that encode for proteins involved
in cancer development and proliferation [105,106]. miR-1 can also target the lncRNA UCA1, thus
inhibiting its expression and subsequently increasing cell apoptosis and motility [107].
Members of the let-7 family are tumour suppressor miRNAs that inhibit the MAPK/ERK
pathway [108]. On the contrary, there are miRNAs that enhance cancer development and progression.
A recent study on miR-10b showed that this miRNA is overexpressed in several types of cancer,
including oesophageal cancer, breast cancer and glioma; in these systems, miR-10b acts to promote
cell mobility and invasiveness by targeting an important gene involved in these processes and
enhancing its activity [109]. Other similar examples are miR-21, miR-155 and miR-29, which are,
in fact, overexpressed in the respectively cancerous tissue and thus are also related to the poor
prognosis observed in these patients [110–112]. In the last century, evidence regarding the different
roles that miRNAs play in physiological and pathological conditions such as cancer has paved the
way for the development of new therapeutic molecules, which can directly act on individually target
miRNAs and enhance their onco-suppressor potential. For example, the first miR-based clinical trial
used an miR-34 mimetic (MRX34, Mirna Therapeutics, Austin, TX, USA) to restore the levels of the
tumour suppressor miR-34 in several types of cancer in which miR-34 has been downregulated [113].
4. miRNAs in Bone
miRNAs are a class of small non-coding RNAs that can regulate gene expression at the
transcriptional and post-transcriptional level simply by binding to specific sequences present on
the target genes. As mentioned above, miRNAs are important regulators of not only pathological
conditions but also physiological processes, including bone development. Osteogenesis is a
complex process characterized by the balance between osteoclastogenesis and osteoblastogenesis.
These activities are controlled by an elaborate signalling network, which includes growth factors,
transcription factors, effectors and miRNAs. Several studies on the role of miRNAs in the three
principle processes involved in the construction of the human skeleton (i.e., osteoclastogenesis,
osteoblastogenesis and chondrogenesis) have elucidated the contributions of miRNAs regarding bone
development. Of the miRNAs discovered, 22 have been identified as inhibitors of the BMP-2-induced
osteoblast differentiation pathway [114]. miR-378, miR-322 and miR-196a have been identified as
involved in BMP signalling by promoting BMP-induced osteogenic differentiation. Other pathways
such as Wnt/β-catenin, Notch and TNF-α signalling are involved in osteoblastogenesis. Many studies
have demonstrated that all these signalling pathways are regulated by different miRNAs, which
can promote the osteogenic differentiation of mesenchymal stem cells (MSCs) [115]. For example,
miR-346 promotes the osteogenic differentiation of MSCs by targeting the glycogen synthase kinase-3β
(GSK-3β), which is important in the activation of β-catenin—a critical factor in the Wnt/β-catenin
pathway [116]. There are reports indicating that high levels of miR-34a inhibit the Notch signalling
pathway resulting in the expression of RUNX2, OSX and OCN, which are fundamental genes in
osteogenesis [117]. Meanwhile, miR-21 promotes the osteogenic differentiation of MSCs by inhibiting
the TNF-α signalling pathway [118]; however, several other miRNAs suppress the osteogenesis of
MSCs. For example, miR-206 levels decrease during osteogenesis differentiation. In fact, it has been
demonstrated that overexpression of miR-206 inhibits osteoblast differentiation, whereas knocking
out miR-206 enhances this process [119]. miR-26a and miR-196a have been described as inhibitors of
osteogenic differentiation of adipose-derived stromal cells [120,121].
There are also miRNA promoters and inhibitors that regulate osteoclastogenesis [122]. Studies
focusing on the promoters have shown that members of the miR-29 family are overexpressed during
osteoclastogenesis to form bone marrow monocytes. This overexpression has also resulted in an
increase of the osteoclast markers TRAP and cathepsin K [123]. In contrast, knockdown of miR-29
inhibited the commitment and migration of pre-osteoclasts, thereby blocking the osteoclastogenesis
process [124].
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miR-223-3p is another well studied miRNA in osteoclastogenesis; downregulation of this miRNA
is characteristic of osteoclast differentiation. Although overexpression of miR-223-3p blocks osteoclast
differentiation, inhibition of this miRNA results in the formation of TRAP-positive osteoclasts [125].
This suggests that maintaining the correct levels of miR-223-3p is necessary to promote appropriate
osteoclast formation. Finally, chondrogenesis is a fundamental process for the development of a
healthy skeleton. Recent studies have observed that miR-140 negatively targets histone deacetylase 4
(HDAC4), particularly expressed in non-hypertrophic chondrocytes. HDAC4 regulate chondrocyte
hypertrophy by inhibiting Runx2. When miR-140 binds to HDAC4, the inhibition on Runx2 is removed,
and chondrocyte hypertrophy, a process that is fundamental for proper endochondral ossification,
is enhanced [126]. In contrast, miR-145 targets Sox9 gene to inhibit the expression of the cartilage
genes while concurrently promoting Runx2 expression [108]. Even though several miRNAs have
been reported to be involved in normal bone development, many other individual miRNAs could
contribute to this activity, and their roles have not yet been discovered; therefore, further studies in this
vein are necessary. Regarding the observations that miRNAs are involved in human diseases and that
the miRNA dysregulation could contribute to the development of cancer, it has become increasingly
clear to scientists that the osteogenesis process could also be influenced by miRNA levels. Recent
studies have shown that primary bone tumours, including Ewing’s sarcoma, chondrosarcoma, OS and
giant cell tumours, change their miRNA expression pattern during their progression [127]. Obviously,
extensive and complete knowledge of the target miRNAs specific to each type of cancer should be
collected for the future development of anti-cancer therapy as well as for the establishment of new
diagnostic methods based on the detection of circulating miRNAs.
5. miRNAs and Primary Bone Tumours
5.1. miRNAs in Chondrosarcoma
As we have previously reported, miRNA expression can be altered in malignancies and play
a fundamental role in tumour progression. This is also the case for primary bone tumours. In fact,
altered miRNA expression has been reported in human chondrosarcoma (COS).
COS, another primary skeletal sarcoma, is characterized by the abnormal production of a specific
cartilage matrix. Although COS can manifest in any bone, this cancer preferentially develops in the
pelvis, humerus, femur, scapula and ribs and can present at any age [128]. Based on the histological
profile, four different subtypes of COS have been identified: (a) conventional COS, which is the
most common (approximately 90% of diagnosed cases); (b) dedifferentiated COS (approximately
10% of diagnosed cases); (c) mesenchymal COS, the most rare but also the most aggressive; and (d)
clear cell chondrosarcoma, a rare variant. COS has been shown to be resistant to the chemotherapy
and radiotherapy. Consequently, an improved prognosis for patients is based on an extremely
precise surgery, but unfortunately, patients with COS usually relapse and inevitably have a poor
prognosis [129]. Currently, the discovery of new molecular diagnostic and prognostic biomarkers
represents the only approach to develop effective and specific treatments against COS.
Therefore, miRNAs could serve as these biomarkers as well as possible novel targets for the
development of future therapies. Several studies have been conducted regarding the roles of miRNAs
in COS progression (Figure 1).
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It has been observed that miR-30a exerts two different functions in COS. Lu et al. reported that
miR-30a could decrease tumour proliferation, migration and invasion using a miR-30a mimic on a
human chondrosarcoma cell line [130]. They also observed that miR-30a expression was negatively
correlated to the tumour grade. In fact, in advanced stage COS, the miR-30a levels were very low.
Furthermore, they reported that one target of miR-30a is SOX4, and this interaction subsequently
reduced cancer cell growth and invasion. SOX4 is a member of the SRY-related HMG box (SOX)
gene family, which is implicated in chondrogenesis [131]. Therefore, SOX4 is a key gene in COS
progression. Interestingly, Lu et al. reported that in cancerous tissues with lower levels of miR-30a,
SOX4 is overexpressed. In summary, this study suggested that SOX4 is an oncogene and is regulated
by miR-30a in COS cells, thus highlighting the important role of miR-30a as a tumour suppressor [130].
Additionally, Jiang et al. reported that downregulation of miR-30a enhances cancer progression.
miR-30a negatively targets RUNX2 in COS cells, and inhibits to this gene to enhance the cancer
invasion [132]. SOX9, another member of the SOX family, is overexpressed in COS and has been
implicated in cancer progression [133]. A recent study showed that downregulation of SOX9 increases
the apoptosis rate [134]. One of the target genes of SOX9 is ETV5 [135], an effector of EMT and a
metastatic target in cancer. Mak et al. investigated the regulation of these two genes and discovered
that miR-145, which has reduced expression in COS, targets and inhibits SOX9. The inhibition of SOX9
is responsible for the downstream activation of ETV5, which then activates MMP-2 and results in the
induction of invasion. Therefore, miR-145 suppresses COS metastasis [136].
Regarding the role of miRNAs in response to chemotherapy and radiotherapy, Tang et al.
demonstrated in a study using different COS cell lines that miR-125b could act as a tumour suppressor
by inhibiting glucose metabolism and targeting the oncogene ErbB2. They also showed that
when miR-125b was downregulated, all the COS cell lines developed resistance to doxorubicin,
a chemotherapy agent. In contrast, overexpression of miR-125b enhanced the cells’ sensitivity to this
drug [137].
Another aspect that has been investigated in COS is cancer cell response to hypoxic conditions.
Hypoxia, which has been reported to be the source of dysregulated gene expression in cancer, is likely
responsible for some cancer traits, one of which is cancer-induced angiogenesis. As described above,
angiogenesis is fundamental for tumour progression and provides cancer cells a means by which to
access the nutrients essential for their proliferation.
Angiogenesis is a complex process characterized by the interplay of pro-angiogenic
(e.g., VEGF/VEGFR and PDGF/PDGFR) and anti-angiogenic factors (e.g., TSP-1/TSP-2). An in vitro
study on COS cells grown in hypoxic conditions has shown that miR-181a is tightly correlated to
the promotion of angiogenesis [138]. It has been demonstrated that miR-181a (once activated) can
directly target the VEGF gene and enhance its expression, thereby inducing angiogenesis. In a
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study of miR-181a function in COS, researchers reported that miRNAs can function as an oncogene.
Furthermore, miR-126 [139], miR-150 [140], and miR-26a [141] have been shown to play a role in
promoting angiogenesis.
Liu et al. also studied the angiogenesis process in COS. By focusing on the role of the chemokine
CCL5 (which has been reported to be related to cancer migration and metastasis in other cancers
as well as), they reported that CCL5 induces VEGF upregulation. This occurs with concomitant
downregulation of miR-199a. In fact, Liu and colleagues demonstrated that co-transfection of COS cells
with a miR-199a mimic completely abolishes CCL5-mediated VEGF expression and angiogenesis [142].
Other recent studies on miRNAs in COS showed that miR-519d, miR-185, and miR-218 play important
roles in COS progression.
miR-519d has been correlated to the invasive capacity of COS because of its ability to interact
with matrix metalloproteinases (MMPs), which are the key molecules that promote tumour metastasis.
Several studies have reported that among the MMPs, MMP-2 is the most critical in COS because it
can degrade type IV collagen, the primary component of cartilage [143]. In their study, Tsai et al.
demonstrated that the migratory potential of COS is elevated in cases with MMP-2 overexpression
and also observed that the concomitant levels of miR-519d were very low. In fact, when the miR-519d
levels are restored, a decrease in the MMP-2 levels and inhibition of the migratory capacity were
observed [144]. Another study conducted by Goudarzi et al. on the role of miR-185 and miR-218
expression in patients with COS showed that (using real-time PCR analysis) patients with a profile
characterized by the contemporary upregulation of miR-218 and the downregulation of miR-185
have a poor survival rate [145]. As indicated by researchers, the observed low survival rate should
be correlated to the decrease of miR-185 levels during COS progression as has been reported in
other cancers [146,147]. In fact, several studies on other tumours have documented that miR-185
overexpression is the basis of inhibiting cancer cell proliferation. At the same time, it has been observed
that while miR-185 is downregulated during cancer progression, miR-218 is overexpressed [148].
In conclusion, Goudarzi et al. demonstrated the specific activities of both these miRNAs in the
enhancing the COS development. miR-218 acts as an oncogene to support COS progression, whereas
activated miR-185 functions like a tumour suppressor [149]. All the discoveries here are illustrated and
summarized in Table 1. Regarding the role of miRNAs in the biological processes of COS, the available
literature provides an initial understanding of their roles in influencing the proliferation, migration,
invasion and chemoresistance of COS. In addition, it encourages further studies to better elucidate
their functions and discover other miRNAs involved in COS. The culmination of this field aims to
identify unique and valid targets for the future development of novel therapies against COS.
Table 1. Cancer-associated miRNAs in chondrosarcoma.
miRNA Function in Chondrosarcoma Gene Target Reference
miR-30a Inhibits cancer cell proliferation and invasion (Ts) SOX4, RUNX2 [130–132]
miR-145 Inhibits tumour metastasis (Ts) SOX9 [136]
miR-125b Enhances tumour chemosensitivity (Ts) ErbB2 [137]
miR-181a Promotes cancer angiogenesis (Og) VEGF [138]
miR-126 Inhibits of cancer angiogenesis (Ts) VCAM-1 [139]
miR-150 Promotes cancer angiogenesis (Og) VEGF [140]
miR-26a Inhibits of cancer angiogenesis (Ts) PIK3C2alpha/Akt/HIF-alpha pathway [141]
miR-199a Inhibits of cancer angiogenesis (Ts) CCL5 [142]
miR-519d Inhibits tumour metastasis (Ts) MMP2 [144]
miR-218 Promotes COS progression (Og) BM1 [145]
miR-185 Inhibits COS proliferation and invasion (Ts) c-Met, DNMT1 [145]
Ts: Tumour suppressor; Og: Oncogene.
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5.2. miRNAs in Osteosarcoma
OS, another primary bone tumour, often occurs in children and adolescents [150]. Based on the
histological analysis, it has been observed that several subtypes of OS (including COS) exist. Among
them, the most commonly diagnosed is conventional OS, which can be osteoblastic, chondroblastic
or fibroblastic depending on the histology. OS principally arises from the metaphysis regions of the
long bones where there is active bone remodelling, suggesting that the initial onset of this cancer is
likely because of dysregulated or inappropriate signalling during remodelling. Currently, despite
the availability of multimodal therapy (i.e., surgical resection of the tumour bulk combined with
chemotherapy and/or radiotherapy), the 5-year survival rate of OS remains lower than 70% [151].
This poor survival rate is why OS is currently the second leading cause of cancer-related death in
children. Obviously, the recent discovery of miRNAs has been studied as a possible solution to better
understanding the molecular basis of the biology of this aggressive bone cancer. Consequently, many
studies have been conducted regarding the association of miRNAs with human cancers, including
OS, [127]. In relation to this, we have decided to summarize all the research that has been conducted
in the last year regarding the expression of miRNAs (Figure 2) and the two principle roles of miRNAs
in the progression of OS. These two areas are their role in the acquired resistance to multidisciplinary
treatments and how they contribute to cancer development and progression.Molecules 2017, 22, 417 11 of 28 
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5.2.1. miRNAs as New Players in Osteosarcoma Chemosensitivity and Chemoresistance:
The Latest Discoveries
An important aspect in which miRNAs have been implicated in cancer is the development of
chemosensitivity and chemoresistance [152], with OS [153] presenting some of the most aggressive
characteristics and most resistant responses to therapies. One component of the multidisciplinary
therapeutic approach against OS is radiotherapy, which is usually performed after surgery to
ensure elimination of the entire tumour bulk. Unfortunately, several cases of radioresistance have
been reported [154]. Consequently, it became clear that to understand the cellular mechanisms of
chemotherapy and radiotherapy resistance, it will be useful to identify molecules that are specific
to OS not only to improve the knowledge base of OS biology but also to develop therapies to target
these molecules; this approach could be more efficient and less invasive. In relation to this, we have
identified many studies published within the last year that focused on which miRNAs exert functions
in OS.
In their in vivo and in vitro studies, Dai et al. detected the presence of the human apurinic/
apyrimidinic endonuclease/redox effector factor (APE1) in OS cells; this protein is responsible for
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repairing DNA damage caused by ionizing radiation and the subsequent presence of reactive oxygen
species. In fact, overexpression of APE1 has been reported in several cancers [155–157]. Dai and
colleagues also demonstrated not only overexpression of APE1 but also simultaneous downregulation
of miR-513a-5p. Interestingly, the levels of miR-513a-5p were higher when APE1 is knocked down;
therefore, there exists an inverse relationship between miR-513a-5p and APE1 expression. Furthermore,
they demonstrated that restoring the levels of miR-513a-5p can sensitize the cells to ionizing radiation.
This negatively targets APE1, and decreased expression of this gene enhances the radiosensitivity and
induces subsequent apoptosis [158].
The other therapeutic treatment targeting OS that is combined with surgery and radiotherapy is
adjuvant chemotherapy, which is based on the use of cisplatin (Cis), doxorubicin (Dox), methotrexate
(Met) and adriamycin (Adr). Similar to radiotherapy, many OS patients begin to demonstrate
chemoresistance to chemotherapy. Therefore, scientists have started to investigate the reason for
this phenomenon and studied the role of miRNAs on the sensitivity of cancers to chemotherapeutic
agents. Within the last year, miR-21, miR-224 and miR-138 appeared on the oncology research scene as
primary players in the cancer response to chemotherapy [159–161].
miR-21 was shown to be upregulated in several tumours (i.e., colorectal, lung, breast and liver) as
well as in OS [162–165]. miR-21 targets several genes that act for the most part as tumour suppressors
which inhibit cell apoptosis, cell signalling, cell proliferation and migration.
Vanas et al. observed that a reduction of miR-21 activity leads to an inhibition of cell proliferation
and migration in OS cell lines, whereas upregulation of miR-21 accelerates the doubling rate of these
cells. Furthermore, they also demonstrated that miR-21 expression confers chemoresistance to OS cells
by decreasing the cellular sensitivity towards Cis by targeting Spry1 and Spry2 genes [159]. However,
this activity has no effect on the sensitivity to either doxorubicin or methotrexate. This aspect has
been observed also in other tumours [166,167]. Geng et al. demonstrated that low levels of miR-224
in OS cell lines and tissues should be correlated with a shorter survival outcome. In their study, they
demonstrated that overexpression of miR-224 in OS cell lines could inhibit proliferation, migration
and invasion and as well as increase the sensitivity to Cis. All these effects are controlled by the gene
Rac1, which is a direct target of miR-224. The same study also reported that Rac1 is upregulated
in OS cell lines and tissues and is responsible for the tumour progression and the development of
chemoresistance to Cis. Interestingly, Rac1 downregulates miR-224. Therefore, Geng and colleagues
showed that there is an inverse correlation between Rac1 and miR-224 and that miR-224 overexpression
in OS cells represses Rac1 and enhances the chemosensitivity to Cis [161]. Obviously, the repression
of miR-224 by Rac1 is an indicator of possible chemoresistance, and, accordingly, a poor survival
rate. The more recent miRNA that was shown to be involved in Cis resistance is miR-138, which has
been observed to have reduced expression in OS tissue than in normal tissue. This decrease might
be related to its tumour suppressor capacity. As scientists have observed, if the levels of miR-138
are restored, there is a dramatic inhibition of cell proliferation and invasion as well as an increase of
chemosensitivity to Cis. They also demonstrated that the change in chemosensitivity can be partially
abolished by overexpression of the EZH2 gene, which can block the activity of caspase-3, a critical
enzyme for apoptosis.
Therefore, this study revealed that in OS, EZH2 is the specific target gene for miR-138 and that this
miRNA acts as a tumour suppressor in OS by enhancing the chemosensitivity to Cis [161]. In contrast,
Wang et al. demonstrated for the first time that miR-367 plays a key role in the development of
chemoresistance in OS [168]. Recent studies revealed that miR-367 executes several functions in
tumours [169–171] and acts as an onco-miRNA in OS. In this study, they observed that the OS cell lines
that overexpress miR-367 exhibit strong resistance to treatment with adriamycin (Adr). This effect is
mediated by the decrease of the expression of the genes KLF4, Bax and cleaved caspase-3, all of which
are related to the apoptotic process and are targets of miR-367. In fact, when miR-367 expression is
downregulated, Adr treatment of OS cells results in apoptosis.
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In the end, two other miRNAs (miR-140-5p and miR-184) have been identified as participating
in the mechanisms of resistance to therapeutic treatments in OS. Several previous studies have
demonstrated that cancer cells use autophagy to ameliorate the effects of therapeutic stress, which
contribute to the development of chemoresistance [172,173]. Therefore, this ongoing consideration
led Wei et al. to investigate the role of autophagy in OS cancer cells. It has been observed that OS
cells treated with doxorubicin (Dox) and Cis presented an increase in miR-140-5p, which stimulates
autophagy. Therefore, upregulation of miR-140-5p inhibits cell survival and chemoresistance, inducing
autophagy [174]. The other miRNA involved in the chemoresistance process is miR-184, which has
been studied in OS cell lines by Lin et al. They showed that treatment with Dox induces time-dependent
expression of miR-184 in OS cell lines. In this study, it was observed that miR-184 reduces the number of
apoptotic cells after treatment by targeting and inhibiting the BCL2L1 gene, one of the genes involved in
the apoptotic process. Therefore, upregulation of miR-184 and suppression of BCL2L1 (which inhibits
apoptosis) increased the resistance of OS cells to Dox. This study also proved that downregulating the
expression levels of miR-184 led to an increase of Dox-induced apoptosis [175]. In conclusion, several
studies have reported the discovery that miRNAs are involved in the sensitivity of OS cells to several
therapeutic agents, with the final aim of understanding which molecular mechanisms confer resistance
to treatments, identifying which miRNAs could be biomarkers of chemoresistance and developing
targets for future therapies based on increased sensitivity to chemotherapy and radiotherapy. All the
discoveries here are illustrated and summarized in Table 2.
Table 2. Associated miRNAs to response to chemo- and radiotherapy in osteosarcoma.
miRNA Function in Osteosarcoma—Response to Therapies Gene Target Reference
miR-513a-5p Induce radiosensitivity (Ts) APE1 [158]
miR-21 Increase cell proliferationPromote chemosensitivity to Cis (Og) Spry1Spry2 [159]
miR-224 Inhibit cell proliferation and migrationIncrease sensitivity to Cis (Ts) Rac1 [160]
miR-138 Inhibits cell proliferation and migrationIncreases chemosensitivity to Cis (Ts) EZH2 [161]
miR-367 Promotes metastasis and EMTInduce chemoresistance to Adr (Og) Bax, Cleaved Caspase-3 KLF4 [168]
miR-140-5p Induces cell apoptosisDecreases the chemoresistance (Ts) IP3k2 [174]
miR-184 Inhibits cell apoptosisPromotes chemosensitivity to Dox (Og) BCL2 L1 [175]
Ts: Tumour suppressor; Og: Oncogene; EMT: Epithelial-mesenchymal transition; Cis: Cisplatin; Adr: Adriamycin;
Dox: Doxorubicin.
5.2.2. miRNAs and the Biology of Osteosarcoma: Latest Discoveries
Regarding the role of miRNAs in cancer progression, several studies have unravelled the
dysfunction and dysregulation of miRNAs that can result in the development of OS. In identifying
the latest studies on miRNAs in OS, we found that with the last year, new miRNAs involved in
OS progression have been identified and could be either tumour promoters (oncomiRs) or tumour
suppressors. The new oncomiRs that have been described are miR-21, miR-92b, miR-603, miR-130a,
miR-488, miR-301a, miR-9 and miR-130b.
Lv et al. found that miR-21 was overexpressed in the human OS cell line MG63 [176] compared
to the healthy foetal osteoblastic cell line hFOB1.19. miR-21 has been observed to be involved in
regulating tumour progression and acting as a oncomiR by targeting and negatively regulating the
PTEN gene, which was one of the first tumour suppressor genes identified [177]. Another miRNA
related to the PTEN gene is miR-130a. An in vitro study of several types of OS cell lines revealed
that upregulation of miR-130a induces cell proliferation, invasion, migration and EMT. Chen et al.
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also demonstrated that when PTEN is downregulated in OS, miR-130a is upregulated, and vice versa.
Furthermore, restoring PTEN expression ameliorates the effects of miR-130a, demonstrating both the
oncogenic role of miR-130a and its link with PTEN [178]. miR-130b, another member of the miR-130
family, is involved in OS progression similar to its activity other tumours [179,180].
Li et al. described that miR-130b is expressed at high levels in OS cells and promotes proliferation
by binding NKD2, which leads to the suppression of Wnt signalling, the consequent inhibition of
apoptosis and the promotion of proliferation [181]. The RECK gene is another tumour suppressor
that is the target of the miRNA mi-92b as observed by Zhou et al. They found that miR-92b was
upregulated in OS cell lines, whereas RECK was downregulated [182]. This upregulation has been
reported to increase OS cell proliferation, invasion and migration by targeting the 3′-UTR of RECK
and inhibiting its activity [182] by consequently blocking its ability to inhibit the metalloproteinases
(MMPs) [183]. This change in activity enhances OS invasion and leads to a poor prognosis. The BRCC2
gene, a proto-oncogene expressed in several cancers, has been reported to prevent apoptosis in several
cancer cell types [184–186]. BRCC2 is the target of the miR-603, which, as Ma et al. demonstrated, is
often overexpressed in patients with OS and/or with metastases. Their study also showed that OS
growth was enhanced by translational inhibition induced by the interaction between miR-603 and
BRCC2, indicating that miR-603 acts as a powerful oncogene [187]. A recent report by Fenger et al.
on the importance of miRNAs in OS [188] revealed that a canine model of OS demonstrated high
similarity with human OS at the molecular level [189]. Furthermore, they demonstrated for the first
time that miR-9 was upregulated in a canine OS cell line. miR-9 is known to perform several different
functions in different cell types; for example, it can inhibit tumour growth in some cases but stimulate
proliferation in others [190,191]. Fenger and colleagues also showed that in OS, miR-9 enhances cell
migration and invasion, thereby promoting metastasis [188]. Their results perfectly aligned with those
of recent studies regarding the upregulation of miR-9 in human OS [191]. The data obtained also paved
the way to the idea that overexpression of miR-9 could be a prognostic marker of OS behaviour.
Although Fenger et al. investigated on miR-9 in OS, Ni et al. showed not only that miR-301a
is overexpressed in OS cell lines but also that this miRNA enhances cell migration and inhibits
apoptosis [192]. Therefore, they confirmed the carcinogenic function of miR-301a in OS, which was
only observed in others cancers [193,194]. Zhou et al. investigated the activated pathways in OS cells
and tissues during hypoxia. The results indicated that there is enhanced expression of miR-488 at the
transcriptional level and that this upregulation promotes cell proliferation as well as reduces apoptosis
and chemosensitivity. The mechanism responsible for this change in activity is the interaction of
mi-488 with the predicted sequence in the 3′UTR of the Bcl-2-interacting mediator of cell death (Bim)
gene [195]. All the discoveries here are illustrated and summarized in Table 3.
Table 3. Latest discovered cancer-related oncomiRs in osteosarcoma.
miRNA Function in Osteosarcoma Gene Target Reference
miR-21 Enhance the tumor progression (Og) PTEN [176]
miR-130a Enhance cell proliferation and invasionPromote the EMT (Og) PTEN [178]
miR-130b Enhances cancer cells doubling (Og) NKD2 [179,180]
miR-92b Enhance cell proliferation and invasion (Og) RECK [182]
miR-603 Enhance cell proliferation and invasion (Og) BRCC2 [187]
miR-9 Enhance cell proliferation and invasion (Og) GSN [188,191]
miR-301a Enhance cell proliferation and migrationInhibit apoptosis (Og) CDC14A [192]
miR-488
Enhance cell proliferation and migration
Inhibit apoptosis
Reduce chemosensitivity (Og)
Bim [195]
Og: oncogene; EMT: Epithelial-mesenchymal transition.
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Next, although there are many studies that have reported the possible existence of new oncomiRs
in OS, there is an increasing number of studies that have shown the first indications of new tumour
suppressor miRNAs in OS. The latest tumour suppressor miRNAs in OS are miR-26a, miR-491-5p,
miR-192, miR-22, miR-205, miR-506, miR-497, miR-34a, miR-203, miR-193a-3p, miR-193a-5p, miR-143,
miR-182, miR-198, miR-874, miR-4262, miR-101, miR-409-3p, miR-124, miR-133a, miR-223 and miR-363.
Li et al. investigated on miR-26a, which has been observed to be involved in osteogenesis [196] and
in the differentiation of several cell types [197,198]. They demonstrated that miR-26a is downregulated
OS-derived cancer stem cells (OS-CSCs) and observed that on the contrary, this upregulation decreases
the expression of stem cell markers and the capacity to form sarcospheres from OS-CSCs [199].
These effects have been linked to the miR-26a target Jagged1. Jagged1 is a component of the
Notch signalling pathway that, when altered, results in the loss of stemness. Therefore, miR-26a
is an tumour suppressor in OS [196]. miR-491-5p has been shown to be downregulated in some
tumours [200–202] and upregulated in others, thus, this miRNA is involved in the inhibition of
tumour growth [203,204]. Yin et al. decided to investigate which role miR-491-5p plays in OS, and
they reported that it is downregulated in OS cells and tissues; however, when the miR-491-5p levels
were restored, they noticed that this miRNA inhibited tumour growth by targeting and negatively
regulating the forkhead-box p4 (FOXP4) gene. FOXP4, a member of the FOXP subfamily, can enhance
cancer proliferation and migration by targeting matrix metalloproteinase-9 (MMP9), thus acting as
an oncogene [200]. This is one explanation as to why miR-491-5p is downregulated in OS—because
it acts as a tumour suppressor via knockdown of FOXP4. Wang et al. decided to clarify the role of
miR-192 in OS [205], which has been previously reported to be dysregulated in several cancers as well
as in OS [206,207]. They reported for first time that miR-192 was downregulated in OS cells, and after
transfection of a miR-192 mimic into OS cells, they observed an inhibition of cancer progression via
miR-192 binding to its specific target, the TCF7 gene [205]. Wang and colleagues also demonstrated the
tumour suppressor potential of miR-192 and the important link between this and the TCF7 gene, an
emerging factor important not only in the inflammatory process but also in cancer [208,209]. Studying
the biology of cancers has revealed that the enzyme ATP citrate lyase (ACLY) [210], a fundamental
enzyme for the de novo lipogenesis [211], is usually upregulated within the tumour and that miR-22
targets this gene as shown by Xin et al. [212].
They reported that miR-22 could be a tumour suppressor because targeting ACLY leads to
inhibition of lipid metabolism and consequent cell proliferation and migration. Additionally, miR-205
is a tumour suppressor miRNA. In fact, Zhang et al. reported that the levels of miR-205 are low in
both OS tissues and cells [213]; however, elevated levels caused an inhibition of proliferation in OS cell
lines. Zhang et al. also showed that one target of miR-205 is the RUNX2 gene, which is a key gene in
osteogenesis [214,215]. They demonstrated that overexpression of miR-205 blocks proliferation and
metastasis in OS due to knockdown of RUNX2 by miR-205 [213].
These data indicated the tumour suppressor role of miR-205. In addition, Yang et al. investigated
the role of miR-205 as a tumour suppressor in OS and showed that there is a link between miR-205
and the TGF-α gene [216]. In fact, although miR-205 is downregulated in cancer, TGF-α is upregulated.
Their studies have demonstrated that miR-205 targets TGF-α, which leads to an increase in the
apoptosis rate by halting cells in G0/G1 phase and decreasing cell invasion [195]. Another tumour
suppressor miRNA identified in OS is miR-506. Overexpression of miR-506 can suppress proliferation
and enhance apoptosis by either targeting the AEG-1 gene or inhibiting the Wnt/β-catenin signalling
pathway, as reported by Yao et al. [217]. They also noticed that AEG-1 could serve as a biomarker in
OS because it is often elevated in patients with a poor prognosis. Ge et al. and Ruan et al. have both
investigated the effects of the tumour suppressor miR-497 in OS [218,219] based on the observation
that miR-497 has been observed to act as a tumour suppressor in other cancers. Ge et al. investigated
the role of miR-497 in an OS cell line and in vivo using a nude mouse model and obtained similar
results in both models. They demonstrated that miR-497 overexpression inhibits tumour growth and
the metastatic process as well as enhances the apoptotic rate [218]. All these effects could be related to
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the ability of miR-497 to target several genes. However, Ruan et al. showed that the inhibitory effect
of miR-497 on OS progression is related to targeting of the AMOT gene, which is very important in
cell migration and cancer-induced angiogenesis, as observed in breast cancer [220]. Thus, Ruan et al.
reported that the overexpression of miR-497 causes a significant decrease in angiomotin expression by
negatively targeting the AMOT gene. In contrast, when miR-497 is downregulated, elevated expression
of angiomotin has been observed, which is related to a poor prognosis [219].
Chen et al. investigated the activity of miR-34a and miR-203 in human OS cells [221]. First, they
observed the overexpression of Survivin in OS, which has been associated with the promotion of
tumour progression and metastasis. For the first time, this group showed that miR-34a and miR-203
are the only two miRNAs capable of targeting Survivin. The result of this interaction is the inhibition
of the tumour progression and the induction of apoptosis and chemosensitivity [221]. Another set
of tumour suppressors miRNAs includes miR-193-3p and miR-193-5p. Pu et al. indicated that the
effects of these miRNAs are because they target and inhibit the Rab27b gene and the SRR gene,
respectively. Both these genes appear to facilitate the invasive/metastatic phenotype of OS. Therefore,
for the first time, miR-193-3p and miR-193-5p have been described as suppressors of metastasis in
OS [222]. In fact, researchers have observed that when these two miRNAs are downregulated, the
levels of Rab27b and SRR are no longer diminished, and the subsequent risk of metastasis is elevated,
and the prognosis is poor. miR-143 is another miRNA with reduced expression in cancer. Li et al.
demonstrated that the reason is because miR-143 is a tumour suppressor that targets the Bcl-2 gene,
which activates the caspase-3, a pro-apoptotic enzyme [223]. Therefore, when miR-143 is upregulated,
there is inhibition of OS growth. Several previous studies have identified miR-182 as an oncogene in
different tumours [224,225], but Bian et al. recently demonstrated how this acts as a tumour suppressor
in OS [226]. In fact, when miR-143 is upregulated, there is an increase in apoptosis and a decrease in
invasion of OS. In a study on OS by Zhang et al. suggested that the observed miR-198 levels were
lower than normal, which might be related to the OS stage and the presence of distant metastases [227].
In relation to this first observation, they demonstrated that overexpression of miR-198 inhibits OS cell
proliferation, migration and invasion in vitro by targeting and inhibiting ROCK1 activity, which is
overexpressed in OS cell lines and tissues [227].
Another miRNA that appears to be dysregulated in cancer is miR-874. Dong et al. investigated its
role in OS and found that the restoration of miR-874 levels inhibits the OS progression by targeting
E2F3, a key factor in cell cycle progression [228]. Another study showed the existence of an association
between miR-4262 and osteopontin (OPN) in OS [229]. OPN was recently recognized as an important
gene in the process of metastasis [230,231]. After observing that OS patients with low levels of
miR-4262 had a poor prognosis, Song et al., studied miR-4262 and discovered that high levels of
miR-4262 promote its activity as a tumour suppressor, and knocked down OPN, which blocked tumour
invasion. In contrast, downregulation of miR-4262 prevents its targeting of OPN, thus resulting in
increased OS invasion [229]. Wang et al. observed that miR-101 acts as tumour suppressor in OS
by targeting c-FOS, thereby inhibiting cell proliferation [232]. Regarding the role of miR-490-3p in
cancer metastasis [233,234], Wu et al. decided to investigate its role in OS metastasis [235]. Their study
demonstrated that overexpression of miR-409-3p reduced OS cell migration and invasion and that this
effect was mediated by targeting catenin-δ1, which has been described as an oncogene via aberrant
regulation of Rho GTPases and the transcriptional activation of other oncogenes [235]. Within the last
year, two groups have studied miR-124 in OS [236,237]; the first demonstrated that upregulation of
miR-124, which is often downregulated in OS cells, blocks proliferation and invasion by targeting
the SPHK1 gene. SPHK1 has been reported to be involved in several cellular processes including
cancer metastasis. Hence, Zhou et al. have described for the first time an association between
miR-124 and SPHK1 [236]. The other group showed the tumour suppressor activity of miR124 and
demonstrated that this activity is related to targeting B7-H3, a protein that promotes uncontrollable
proliferation and invasion [237]. Thus, Wang et al. demonstrated that elevated levels of miR124
can significantly suppress in vitro cell proliferation and invasion by targeting B7-H3 [237]. A study
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by Chen et al. regarding the involvement of miR-133a in OS progression indicated that miR-133a
is a tumour suppressor. This is related to its association with IGF-1R, which regulates cancer cell
progression and indirectly targets the AKT/ERK signalling pathway [238]. Another miRNA that has
been recognized to play the role as a tumour suppressor in OS is miR-223. It has been shown that this
miRNA could be a biomarker to stratify the clinical stages of OS. In fact, Dong et al. demonstrated that
OS patients with lower levels of miR-223 tend to have distant metastases and a worse prognosis than
OS patients with higher levels of miR-223 [239]. The most recent miRNA that was discovered to act as
a tumour suppressor in OS is miR-363, which inhibits tumour progression and metastasis by targeting
MAP2K4 [240]. All the discoveries here are illustrated and summarized in Table 4.
Table 4. Latest discovered cancer related tumor suppressors miRs in osteosarcoma.
miRNA Function in Osteosarcoma Gene Target Reference
miR-26a Loss of stem like properties in CSCs (Ts) Jagged1 [196]
miR-491-5p Inhibit tumour growth and metastasis (Ts) FOXP4 [200]
miR-192 Inhibit tumour progression (Ts) TCF7 [205]
miR-22 Inhibit lipid metabolism, cell proliferationand invasion (Ts) ACLY [212]
miR-205 Inhibit cell proliferation and metastasisIncrease of the apoptotic cell rate (Ts)
RUNX2
TGFα [213,216]
miR-506 Inhibit cell proliferationEnhance apoptosis (Ts) AEG-1 [217]
miR-497 Enhance apoptosisInhibit cell proliferation and metastasis (Ts) AMOT [218,219]
miR-34a Inhibit tumor progressionInhibit metastasis(Ts) Survivin [221]
miR-203 Inhibit tumor progressionInhibit metastasis (Ts) Survivin [221]
miR-193-3p Inhibit metastasis (Ts) Rab27B [222]
miR-193-5p Inhibit metastasis (Ts) SRR [222]
miR-143 Inhibit tumor growth (Ts) Bcl-2 [223]
miR-182 Enhance apoptosisInhibit invasion process (Ts) PDCD4 [226]
miR-198 Inhibit cell proliferation and invasion (Ts) ROCK1 [227]
miR-874 Inhibit of tumor growth (Ts) E2F3 [228]
miR-4262 Inhibit tumor invasion (Ts) OPN [229]
miR-101 Inhibit cell proliferation and invasion (Ts) c-FOS [232]
miR-409-3p Inhibit cell invasion and metastasis (Ts) Rho GTPases [235]
miR-124 Inhibit cell proliferation and invasion (Ts) SPHK1B7-H3 [236,237]
miR-133a Inhibit tumor growth (Ts) AKT/ERK signaling pathway [238]
miR-223 Inhibit cell invasion (Ts) Ect2 [239]
miR-363 Inhibit cell growth and metastasis (Ts) MAP2K4 [240]
Ts: Tumor suppressor; CSCs: Cancer stem cells.
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6. Conclusions
In summary, since the discovery of ncRNAs, researchers around the world have begun to study
the effects of these molecules in human cancers. Among these, the confirmed presence of miRNAs
in cancers has elevated interest in their study. Additionally, miRNAs have recently emerged as ideal
molecules that could be used as diagnostic and prognostic biomarkers in many cancers. Furthermore,
for rare and aggressive cancers (e.g., osteosarcoma and chondrosarcoma), miRNAs could provide
a solution in the development of new therapies that will focus on either inhibiting onco-miRNAs
or inducing the expression of tumour suppressor miRNAs. For this reason, many studies have
been conducted regarding miRNAs in chondrosarcoma and OS. The important discoveries, which
we have described in this review, show how the knowledge of miRNAs in these bone tumours is
rapidly expanding.
Although it is clear that this is the best approach in researching valid therapies for these cancers,
more in-depth examinations should be conducted to go beyond the challenging problems; for example,
identifying a standardized method to detect miRNAs and establishing an ideal in vivo delivery system
to modulate miRNA expression. This would allow research studies on miRNAs to translate to clinical
applications, with the final goal of using these targets to develop anti-cancer drugs.
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